The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
The practice's commitment to listening and believing patients ensures concerns are heard and treatment plans align with individual goals and values
de Wit HM, Vervoort GM, Jansen HJ, et al
In January, Jaguar Health subsidiary Napo Pharmaceuticals filed a patent application for Mytesi to treat the GI side effects common with GLP-1 and GIP treatments used for obesity
Liu J, Zhang M, Qin C, Wang Z, Chen J, Wang R, et al
Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex Glycyl-L-histidyl-L-lysine-Cu2+ 8